Skip to main content

Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection

Objective

The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4+ T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planned novel strategy is to successfully combine immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents, in a proof-of-concept phase IIa clinical trial. HIVACAR project will lead to a reduction of the actual costs related to HIV treatment and management and of the social public health as well as an improvement in the patients’ quality of life. HIVACAR project has been conceived under the framework of responsible research and innovation, so patients and other stakeholders will have a key role from the inception of the project until obtaining the results. Patients will be perfectly aware of how this therapy has been conceived and the real impact and change in their actual quality of life, as well as how the clinical trial has been designed and the consequences of participating in it. In addition, patients (and the general population) will tailor the project and its results dissemination and communication. This patient engagement will not be limited to the clinical trial but also to the rest of the activities of the project, so patients and the general society will be aware of how the research is developed and can include the patients’ point of view in the research activities. In addition, the socio-economic and psycho-social impact of the new treatment will be also analysed so overwhelming data on the benefits and impact of the new treatment will be obtained and shown to all the stakeholders.

Field of science

  • /medical and health sciences/health sciences/public and environmental health
  • /medical and health sciences/health sciences/infectious disease/RNA virus/hiv

Call for proposal

H2020-SC1-2016-RTD
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Address
Calle Rossello 149 Puerta Bjs
08036 Barcelona
Spain
Activity type
Other
EU contribution
€ 2 859 183,75

Participants (14)

ETHERNA IMMUNOTHERAPIES

Participation ended

Belgium
EU contribution
€ 215 000
Address
Galileilaan 19
2845 Niel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA
Spain
EU contribution
€ 714 375
Address
Carretera De Canyet
08916 Barcelona
Activity type
Research Organisations
AARHUS UNIVERSITET
Denmark
EU contribution
€ 496 250
Address
Nordre Ringgade 1
8000 Aarhus C
Activity type
Higher or Secondary Education Establishments
VRIJE UNIVERSITEIT BRUSSEL
Belgium
EU contribution
€ 198 360
Address
Pleinlaan 2
1050 Brussel
Activity type
Higher or Secondary Education Establishments
THE ROCKEFELLER UNIVERSITY NOT FOR PROFIT CORPORATION
United States
EU contribution
€ 706 250
Address
York Avenue 1230
10065 New York
Activity type
Higher or Secondary Education Establishments
AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS
Spain
EU contribution
€ 238 063
Address
Calle Serrano 117
28006 Madrid
Activity type
Research Organisations
Simon Fraser University
Canada
EU contribution
€ 0
Address
University Drive 8888
V5A 1S6 Burnaby
Activity type
Higher or Secondary Education Establishments
EUROPEAN AIDS TREATMENT GROUP EV
Germany
EU contribution
€ 150 000
Address
Mettmanner Strasse 24-26
40233 Dusseldorf
Activity type
Other
UNIVERSIDAD COMPLUTENSE DE MADRID
Spain
EU contribution
€ 128 750
Address
Avenida De Seneca 2
28040 Madrid
Activity type
Higher or Secondary Education Establishments
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK
France
EU contribution
€ 309 275,75
Address
5 Rue Watt
75013 Paris
Activity type
Research Organisations
ASPHALION SL
Spain
EU contribution
€ 175 000
Address
Calle Tarragona, Numeros 151-157, Planta 10, Bloqu
08014 Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 216 236,25
Address
3 Avenue Victoria
75000 Paris
Activity type
Research Organisations
ZABALA INNOVATION CONSULTING, S.A.
Spain
EU contribution
€ 273 125
Address
Paseo Santxiki 3 Bis
31192 Mutilva Alta Navarra
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AELIX THERAPEUTICS SL

Participation ended

Spain
EU contribution
€ 5 242,25
Address
Calle Baldiri Reixac, 4-8
08028 Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)